DAPA-HF · 2019 · New England Journal of Medicine
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
Dapagliflozin reduces heart-failure worsening and CV death in HFrEF with or without diabetes.
Source publication
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
John J.V. McMurray et al. · New England Journal of Medicine · 2019
Sponsor
AstraZeneca
Principal investigator
—
Population
Chronic Heart Failure With Reduced Ejection Fraction (HFrEF); n=4744
Primary endpoint
Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure.
Methodology notes
Full methodology is under curation. This project aggregates 3 seeded claims across three temporal layers. The replication spec, pre-registered analysis, and version history will appear here as the project matures.
Funding progress
$731K / $2.8M
26%
Funding displayed here is indicative of collaborator interest. Sciync does not broker money, grants, or securities.
Temporal layers
Published findings under validation
1
Active replication in progress
1
Forecast horizons pending resolution
1